DOCSLIB.ORG

Cloning of Another Human Serotonin Receptor (5-HT1F): a Fifth 5-HT1 Receptor Subtype Coupled to the Inhibition of Adenylate Cyclase NIKA ADHAM, HUNG-TEH Kao*, LEE E

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cloning of Another Human Serotonin Receptor (5-HT1F): a Fifth 5-HT1 Receptor Subtype Coupled to the Inhibition of Adenylate Cyclase NIKA ADHAM, HUNG-TEH Kao*, LEE E Proc. Nati. Acad. Sci. USA Vol. 90, pp. 408-412, January 1993 Neurobiology Cloning of another human serotonin receptor (5-HT1F): A fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase NIKA ADHAM, HUNG-TEH KAo*, LEE E. SCHECHTER, JONATHAN BARD, MICHAEL OLSEN, DEBORAH URQUHART, MARGARET DURKIN, PAUL R. HARTIG, RICHARD L. WEINSHANK, AND THERESA A. BRANCHEKt Synaptic Pharmaceutical Corporation, 215 College Road, Paramus, NJ 07652 Communicated by Eric Kandel, September 28, 1992 ABSTRACT An intronless gene encoding an additional 5-HTD10/p receptors. Primers 3.17 and 5.5 [(5'-TGGAATTC- human serotonin (5-1T) 5-HTificee receptor subtype was iso- TGYGYIATHKCICTGGAYMGSTA-3') and (5'-CATIA- lated from a human genomic library with probes obtained from VIRIIARIGGDATRWARAAIGC-3')] were used to amplify degenerate PCR primers used to amplify 5-liT-receptor- 5 ,ug of poly(A)+ RNA from rat brain that was reverse- specific sequences. The highest degree of homology was found transcribed by reverse transcriptase (avian myeloblastosis with the 5-HT1E subtype (70%) and the 5-HTlDa (63%) and virus). PCR was done on single-stranded cDNA as follows: 5-HTlDp3 (60%) receptors. RNA for this gene was detected in 940C for 1 min, 500C for 2 min, and 72TC for 3 min for 40 the human brain but was not detected in kidney, liver, spleen, cycles. After PCR, 90 A.l of the reaction was phenol/ heart, pancreas, and testes. High-affinity (Kd = 9.2 nM) chloroform-extracted and precipitated, treated with T4 DNA 3H-labeled 5-HT binding was detected. Competition studies polymerase, and digested with EcoRI before separation on a revealed the following rank order of potencies for serotonergic 1% agarose gel. The DNA fragment was isolated from the gel, ligands: 5-HT > sumatriptan >> 5-carboxyamidotryptamine kinased, and cloned into pBluescript. Recombinant clones > 8-hydroxy-2(di-1-propylamino)tetralin > spiperone. 5-HT were analyzed by sequencing. One clone, designated S51, produced a dose-dependent inhibition of forskolin-stlmulated was chosen for further study. cAMP accumulation (EC50 = 7.9 nM) in transfected cells. Cloning and Sequencing. A human lymphocyte genomic These properties distinguish this receptor from any previously library (Stratagene) was screened by using the rat S51 frag- characterized and establish a fifth 5-HT1.15&. receptor subtype ment as a probe. The probe was labeled with 32P by the (5-HT1F) coupled to the inhibition of adenylate cyclase. method of random priming (18) and hybridized (19). For subcloning and further Southern blot analysis, DNA was The diverse physiological actions of serotonin (5-HT) are inserted into pUC18 (Pharmacia). Nucleotide sequence anal- mediated by at least four receptor classes: 5-HTlike, 5-HT2, ysis was done by the Sanger dideoxynucleotide chain- 5-HT3, and 5-HT4 (1-3). The 5-HT1like class appears the most termination method (20) on denatured double-stranded plas- heterogeneous. Four human genes encoding 5-HT1.like recep- mid templates with Sequenase (United States Biochemical). tors have been cloned: 5-HT1A (4, 5), 5-HTDa (6, 7), 5-HT1D, Expression. The coding region of clone hL16a was cloned (7-9), and 5-HT1E (10-12). The 5-HT1B receptor has been into vector pcEXV-3 (21), and stable cell lines were obtained cloned (13-15) and is homologous to the 5-HT1Dp receptor by cotransfection (19). One LM(tk-) cell line, L-1F-3, was (14). These 5-HT1like receptors all share an amino acid selected for binding studies; one NIH 3T3 stable cell line homology of at least 50o, high affinity for 3H-labeled 5-HT N-1F-6 was selected for functional studies. ([3H]5-HT), and coupling to the inhibition of adenylate cy- clase activity as a primary coupling pathway. Many addi- Membrane Preparation. Membranes were prepared from tional 5-HT-mediated functional responses do not seem to stably transfected LM(tk-) cells as described (19). Protein correlate with any ofthese cloned receptor subtypes (16, 17). concentrations were determined by the method of Bradford We have used a PCR cloning approach to isolate a human (22). gene that encodes another 5-HT1-lke, receptor, termed 5-HT1F, Radioligand-Binding Studies. [3H]5-HT-(20-30 Ci/mmol; with a pharmacological profile distinct from any serotoner- New England Nuclear; 1 Ci = 37 GBq) binding was done as gic receptor yet described.t Like the other 5-HTl ike recep- described (7). Competition experiments were done by using tors, 5-HT1F couples to the inhibition of adenylate cyclase 10-12 concentrations of drug and 4.5-5.5 nM [3H]5-HT. activity, and this response is blocked by methiothepin. De- Nonspecific binding was defined by 10 A.M 5-HT. Binding tection ofthe mRNA encoding this receptor in the human brain data were analyzed by nonlinear-regression analysis (7). IC50 indicates that binding studies using [3H]5-HT as a ligand values were converted to Ki values using the Cheng-Prusoff require reevaluation. Furthermore, the high affinity of the equation (23). All experiments were done in triplicate. antimigraine drug sumatriptan at this subtype indicates a Adenylate Cyclase Activity. Adenylate cyclase activity was possible role of the 5-HT1F receptor in migraine. determined in initial experiments in LM(tk-) cells, as de- scribed (14). A weak inhibition of forskolin-stimulated ade- EXPERIMENTAL PROCEDURES nylate cyclase (FSAC) (25-30%o) was obtained. Stable cell PCR. The third (III) and fifth (V) transmembrane (TM) Abbreviations: TM, transmembrane; 5-CT, 5-carboxyamido- domains of the following receptors were used to synthesize tryptamine; 5-HT, serotonin (5-hydroxytryptamine); [3H]5-HT, 3H- degenerate primers: 5-HT1A, 5-HT1c, 5-HT2, and the labeled 5-HT; FSAC, forskolin-stimulated adenylate cyclase. *Present address: Department of Psychiatry and Behavioral Sci- ences, Stanford University Medical Center, Stanford, CA 94305. The publication costs of this article were defrayed in part by page charge tTo whom reprint requests should be addressed. payment. This article must therefore be hereby marked "advertisement" tThe nucleotide sequence reported in this paper has been deposited in accordance with 18 U.S.C. §1734 solely to indicate this fact. in the GenBank data base (accession no. L04962). 408 Neurobiology: Adham et al. Proc. Natl. Acad. Sci. USA 90 (1993) 409 5 - H T M D F L N S S D Q N LT S E L L N RMPSK ;S -1 M N I T N C T T E A S M A; R P K T I T E K M 5-HT, M S P L N Q S A E 4 L P Q E A S N R S L N A T E T S E A W D P R T L Q AL 39 c -n 5 - HT, 0 M E E P G A Q C A P P P P A G S E T W V P Q A N L S S A P S O N C S A K D Y I Y Q D S I S L PW:.O KV 5 - H T. Ar M D V L S PGQGNNTTSPPAPFEIT GN TTGr 'S5UV' TVS4 C i9' -. .. :. 5-HI1 , . V S- L-- :- -- L : F. -n L A - Y-XR K-L HHP A N Y I C$sL A-VTXD F- L VAVY 7L4 .. ..................... 5-HTI1 ..L. I C M i.X..tt- V I L...T...T.. L L A & - .......K.- ...-" .V ..N...L.LM.A$. ...... -:.. --....--------- - S L A ...V I ..L..A V L A F 5 HI;),,LT V...... S. .L .L L.T.R.. KL)...... ...... ..t..:...T...GSLATT.LT.......:P....A...PA #:Y - LVS 89 I t.-. L V M L...L....A L I A..X-..A.-.-t....T .. L S F A 5- H T L. N........A .. I. RT~~KtA~~TPANYL1A........O... LS 5-HIHT IT....S.E L ..L I..G I. 1.- I f C A V L G- N A C L E R SVS.....I YL....O N V A N ...........S...LAV T D L M I~~~~~~~~~~~~~~. -..- 5-HT,, i-L--.V14 li02..-F 5.1.S Y R E S V.V S 1 L 124 5-HIH L..-.V..M14 PL-. ..1 I..Y. V- M4 D R -W .K L Y F L: C: £ V - :U S -V LH.C.V..A.D 123 5 - HIT,4 ..-.L,.,.,.V,,.,..N,,-.,.P.,.,,.1 A 139 5-HTI,,, L M IY G R L -G-Q C D U S S C " 150 ..A..S.. ... ... ...... ... - 7 5 HT .. .L L P-'M A A L - VI NKH U'W' :I: L- 13 IV-_ 5-HT, : - - ..A V..... A.. --.... ..-. - .... -.. ........... ..... G T S RD D E l 7 5-HTI iN I : FSAHR K T A K R A L L I- T $ F R R L S P P P S Q 172 .-..: :....:::.:.:::.....: :::..::::::.......... : ..................:.::.: 5 - HIT E~ S K A.: A TI A A Q E E M S D 187 5- HTI,, ..- .:,....-S, - S A K-R PPW K-R- A- A A L UV- F S A E E E V S E 198 5-HT .... D R S D P 2 A -'i5 ,, 5-H C 5 - HT,, I ::::~~~~~~~~~D I Y Y S 21 s 5 - HT ,t, :: ................. :..M:. 2i I.Y T C A Y R R 5- HTI 1 :-.-:CII..-vLvVNv TIDKT D... }I1.GL LYY .T. Y~S..T. .Fi A..FK~.r LI Li G- IY VEA 229L 5-HT. 5-HTI1 .....@ .- ... .... .:.. I A.K.EE V N GQ: VL L.L E S:G E KS l K S V S.T.S K .S i.
Load more

Recommended publications
  • Ayahuasca: Spiritual Pharmacology & Drug Interactions
    Ayahuasca: Spiritual Pharmacology & Drug Interactions BENJAMIN MALCOLM, PHARMD, MPH [email protected] MARCH 28 TH 2017 AWARE PROJECT Can Science be Spiritual? “Science is not only compatible with spirituality; it is a profound source of spirituality. When we recognize our place in an immensity of light years and in the passage of ages, when we grasp the intricacy, beauty and subtlety of life, then that soaring feeling, that sense of elation and humility combined, is surely spiritual. The notion that science and spirituality are somehow mutually exclusive does a disservice to both.” – Carl Sagan Disclosures & Disclaimers No conflicts of interest to disclose – I don’t get paid by pharma and have no potential to profit directly from ayahuasca This presentation is for information purposes only, none of the information presented should be used in replacement of medical advice or be considered medical advice This presentation is not an endorsement of illicit activity Presentation Outline & Objectives Describe what is known regarding ayahuasca’s pharmacology Outline adverse food and drug combinations with ayahuasca as well as strategies for risk management Provide an overview of spiritual pharmacology and current clinical data supporting potential of ayahuasca for treatment of mental illness Pharmacology Terms Drug ◦ Term used synonymously with substance or medicine in this presentation and in pharmacology ◦ No offense intended if I call your medicine or madre a drug! Bioavailability ◦ The amount of a drug that enters the body and is able to have an active effect ◦ Route specific: bioavailability is different between oral, intranasal, inhalation (smoked), and injected routes of administration (IV, IM, SC) Half-life (T ½) ◦ The amount of time it takes the body to metabolize/eliminate 50% of a drug ◦ E.g.
    [Show full text]
  • Product List March 2019 - Page 1 of 53
    Wessex has been sourcing and supplying active substances to medicine manufacturers since its incorporation in 1994. We supply from known, trusted partners working to full cGMP and with full regulatory support. Please contact us for details of the following products. Product CAS No. ( R)-2-Methyl-CBS-oxazaborolidine 112022-83-0 (-) (1R) Menthyl Chloroformate 14602-86-9 (+)-Sotalol Hydrochloride 959-24-0 (2R)-2-[(4-Ethyl-2, 3-dioxopiperazinyl) carbonylamino]-2-phenylacetic 63422-71-9 acid (2R)-2-[(4-Ethyl-2-3-dioxopiperazinyl) carbonylamino]-2-(4- 62893-24-7 hydroxyphenyl) acetic acid (r)-(+)-α-Lipoic Acid 1200-22-2 (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile 207557-35-5 1,1'-Carbonyl diimidazole 530-62-1 1,3-Cyclohexanedione 504-02-9 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol acetate 839705-03-2 1-[2-Amino-1-(4-methoxyphenyl) ethyl] cyclohexanol Hydrochloride 130198-05-9 1-[Cyano-(4-methoxyphenyl) methyl] cyclohexanol 93413-76-4 1-Chloroethyl-4-nitrophenyl carbonate 101623-69-2 2-(2-Aminothiazol-4-yl) acetic acid Hydrochloride 66659-20-9 2-(4-Nitrophenyl)ethanamine Hydrochloride 29968-78-3 2,4 Dichlorobenzyl Alcohol (2,4 DCBA) 1777-82-8 2,6-Dichlorophenol 87-65-0 2.6 Diamino Pyridine 136-40-3 2-Aminoheptane Sulfate 6411-75-2 2-Ethylhexanoyl Chloride 760-67-8 2-Ethylhexyl Chloroformate 24468-13-1 2-Isopropyl-4-(N-methylaminomethyl) thiazole Hydrochloride 908591-25-3 4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butane dione 720-94-5 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine Hydrochloride 28783-41-7 4-Chloro-N-methyl-piperidine 5570-77-4
    [Show full text]
  • The Migraine Attack As a Homeostatic, Neuroprotective Response to Brain Oxidative Stress: Preliminary Evidence for a Theory
    ISSN 0017-8748 Headache doi: 10.1111/head.13214 VC 2017 American Headache Society Published by Wiley Periodicals, Inc. Views and Perspectives The Migraine Attack as a Homeostatic, Neuroprotective Response to Brain Oxidative Stress: Preliminary Evidence for a Theory Jonathan M. Borkum, PhD Background.—Previous research has suggested that migraineurs show higher levels of oxidative stress (lipid peroxides) between migraine attacks and that migraine triggers may further increase brain oxidative stress. Oxidative stress is trans- duced into a neural signal by the TRPA1 ion channel on meningeal pain receptors, eliciting neurogenic inflammation, a key event in migraine. Thus, migraines may be a response to brain oxidative stress. Results.—In this article, a number of migraine components are considered: cortical spreading depression, platelet acti- vation, plasma protein extravasation, endothelial nitric oxide synthesis, and the release of serotonin, substance P, calcitonin gene-related peptide, and brain-derived neurotrophic factor. Evidence is presented from in vitro research and animal and human studies of ischemia suggesting that each component has neuroprotective functions, decreasing oxidant production, upregulating antioxidant enzymes, stimulating neurogenesis, preventing apoptosis, facilitating mitochondrial biogenesis, and/or releasing growth factors in the brain. Feedback loops between these components are described. Limitations and challenges to the model are discussed. Conclusions.—The theory is presented that migraines are an integrated
    [Show full text]
  • PMA-Sio2: Heteropolyacid Catalysis for Michael Addition-Convenient Route to Substituted-3-Indoles
    Available online at www.derpharmachemica.com ISSN 0975-413X Der Pharma Chemica, 2017, 9(13):112-117 CODEN (USA): PCHHAX (http://www.derpharmachemica.com/archive.html) PMA-SiO2: Heteropolyacid Catalysis for Michael Addition-Convenient Route to Substituted-3-Indoles Vijay Kumar Pasala* Deapartment of Chemistry, Osmania University, Hyderabad-500007, Telangana, India ABSTRACT Synthesis of 3-substituted indoles in a hassel-free, ecofriendly manner by treating indoles with α, β-unsaturated carbonyl or nitro compounds under acidic conditions to give good to excellent yields with shorter reaction durations are described. The catalyst is recyclable for three to four times without great loss in the activity. Keywords: Phosphomolybdic Acid (PMA), Substituted indoles, α, β-unsaturated carbonyl compounds, α, β-unsaturated nitro compounds, Michael addition INTRODUCTION Heterocyclic chemistry is one of the quintessential branches of organic synthesis beaconing towards new scaffolds with medicinal values, new methodologies to the existing active principles etc. One among such skeletons is indole. It is perhaps the most common heterocycles in chemistry and its derivatives are obtained from coal pitch, variety of plants or by the bacterial decay of tryptophan in the intestine [1]. Indole derivatives serve as signaling chemicals in plants and animals, as nucleus building blocks (serotonin [2] (A) a crucial neurotransmitter in the central nervous system [3]), as antibacterial [4], antiviral [5], protein kinase inhibitors [6], anticancer agents [7], entheogens (psilocybin (B) causes perceptional changes), hormones (melatonin (C) regulates sleep and wakefulness), antidepressants (roxindole (D), bufotenin (E)), sumatriptan (F) for the treatment of migraine and ondansetron (G) for the suppression of nausea and vastly found in natural products such as alkaloids (Corynanthe, Iboga, and Aspidosperma alkaloids) [8-10], indigoids etc., which originate, either fully or partly, from bio-oxidation of indoles [11].
    [Show full text]
  • Pharmacokinetics, Pharmacodynamics and Drug
    pharmaceutics Review Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of New Anti-Migraine Drugs—Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies Danuta Szkutnik-Fiedler Department of Clinical Pharmacy and Biopharmacy, Pozna´nUniversity of Medical Sciences, Sw.´ Marii Magdaleny 14 St., 61-861 Pozna´n,Poland; [email protected] Received: 28 October 2020; Accepted: 30 November 2020; Published: 3 December 2020 Abstract: In the last few years, there have been significant advances in migraine management and prevention. Lasmiditan, ubrogepant, rimegepant and monoclonal antibodies (erenumab, fremanezumab, galcanezumab, and eptinezumab) are new drugs that were launched on the US pharmaceutical market; some of them also in Europe. This publication reviews the available worldwide references on the safety of these anti-migraine drugs with a focus on the possible drug–drug (DDI) or drug–food interactions. As is known, bioavailability of a drug and, hence, its pharmacological efficacy depend on its pharmacokinetics and pharmacodynamics, which may be altered by drug interactions. This paper discusses the interactions of gepants and lasmiditan with, i.a., serotonergic drugs, CYP3A4 inhibitors, and inducers or breast cancer resistant protein (BCRP) and P-glycoprotein (P-gp) inhibitors. In the case of monoclonal antibodies, the issue of pharmacodynamic interactions related to the modulation of the immune system functions was addressed. It also focuses on the effect of monoclonal antibodies on expression of class Fc gamma receptors (FcγR). Keywords: migraine; lasmiditan; gepants; monoclonal antibodies; drug–drug interactions 1. Introduction Migraine is a chronic neurological disorder characterized by a repetitive, usually unilateral, pulsating headache with attacks typically lasting from 4 to 72 h.
    [Show full text]
  • Selective Labeling of Serotonin Receptors Byd-[3H]Lysergic Acid
    Proc. Nati. Acad. Sci. USA Vol. 75, No. 12, pp. 5783-5787, December 1978 Biochemistry Selective labeling of serotonin receptors by d-[3H]lysergic acid diethylamide in calf caudate (ergots/hallucinogens/tryptamines/norepinephrine/dopamine) PATRICIA M. WHITAKER AND PHILIP SEEMAN* Department of Pharmacology, University of Toronto, Toronto, Canada M5S 1A8 Communicated by Philip Siekevltz, August 18,1978 ABSTRACT Since it was known that d-lysergic acid di- The objective in this present study was to improve the se- ethylamide (LSD) affected catecholaminergic as well as sero- lectivity of [3H]LSD for serotonin receptors, concomitantly toninergic neurons, the objective in this study was to enhance using other drugs to block a-adrenergic and dopamine receptors the selectivity of [3HJISD binding to serotonin receptors in vitro by using crude homogenates of calf caudate. In the presence of (cf. refs. 36-38). We then compared the potencies of various a combination of 50 nM each of phentolamine (adde to pre- drugs on this selective [3H]LSD binding and compared these clude the binding of [3HJLSD to a-adrenoceptors), apmo ie, data to those for the high-affinity binding of [3H]serotonin and spiperone (added to preclude the binding of [3H[LSD to (39). dopamine receptors), it was found by Scatchard analysis that the total number of 3H sites went down to 300 fmol/mg, compared to 1100 fmol/mg in the absence of the catechol- METHODS amine-blocking drugs. The IC50 values (concentrations to inhibit Preparation of Membranes. Calf brains were obtained fresh binding by 50%) for various drugs were tested on the binding of [3HLSD in the presence of 50 nM each of apomorphine (A), from the Canada Packers Hunisett plant (Toronto).
    [Show full text]
  • A Clinical Trial of the Prolactin Inhibitor Metergoline in the Treatment of Canine Pseudopregnancy
    __________________________________________________________Revista Científica, FCV-LUZ / Vol. XII, Nº 6, 712-714, 2002 A CLINICAL TRIAL OF THE PROLACTIN INHIBITOR METERGOLINE IN THE TREATMENT OF CANINE PSEUDOPREGNANCY Estudio Clínico del Inhibidor de la Prolactina Metergolina en el Tratamiento de la Pseudopreñez Canina Gervasio Castex, Yanina Corrada y Cristina Gobello Institute of Theriogenology, Faculty of Veterinary Sciences, National University of La Plata. 60th & 118th st. La Plata. B1900AWV, Argentina. E-mail: [email protected] ABSTRACT de los signos es extremadamente variable en las distintas pe- rras. La metergolina, es esencialmente un antagonista seroto- Canine pseudopregnancy is a syndrome, characterized by ninérgico que inhibe la secreción de prolactina. Un total 24 pe- signs such as nesting, weight gain, mammary enlargement and rras mestizas y de raza, manifiestamente pseudopreñadas, lactation, which appear in nonpregnant bitches 6 to 12 weeks fueron distribuidas en dos grupos de 10 y 14 animales respec- after estrus. The intensity of these signs is extremely variable tivamente: placebo (PL) y metergolina (ME, tratadas con me- among bitches. Metergoline is essentially a serotoninergic an- tergolina 0.1 mg/Kg cada 12 h oral durante 10 días). En los tagonist that inhibits prolactin secretion. A total of 24 cross and días -1,7y14(día 0: comienzo del tratamiento) todos los ani- pure-bred, overtly pseudopregnant bitches, were randomly al- males fueron clasificados en grados de intensidad según los located to two groups of 10 and 14 animals respectively each: signos clínicos de pseudopreñez (II, I, 0). La presencia o au- placebo (PL) and metergoline (ME, treated with metergoline sencia de efectos colaterales también fue evaluada.
    [Show full text]
  • Triptans Step Therapy/Quantity Limit Criteria
    Triptans Step Therapy/Quantity Limit Criteria Program may be implemented with the following options 1) step therapy 2) quantity limits or 3) step therapy with quantity limits For Blue Cross and Blue Shield of Illinois Option 1 (step therapy only) will apply. Brand Generic Dosage Form Amerge® naratriptan tablets Axert® almotriptan tablets Frova® frovatriptan tablets Imitrex® sumatriptan injection*, nasal spray, tablets* Maxalt® rizatriptan tablets Maxalt-MLT® rizatriptan tablets Relpax® eletriptan tablets Treximet™ sumatriptan and naproxen tablets Zomig® zolmitriptan tablets, nasal spray Zomig-ZMT® zolmitriptan tablets * generic available and included as target agent in quantity limit edit FDA APPROVED INDICATIONS1-7 The following information is taken from individual drug prescribing information and is provided here as background information only. Not all FDA-approved indications may be considered medically necessary. All criteria are found in the section “Prior Authorization Criteria for Approval.” Amerge® Tablets1, Axert® Tablets2, Frova® Tablets3,Imitrex® injection4, Imitrex Nasal Spray5, Imitrex Tablets6, Maxalt® Tablets7, Maxalt-MLT® Tablets7, Relpax® Tablets8, Treximet™ Tablets9, Zomig® Tablets10, Zomig-ZMT® Tablets10, and Zomig® Nasal Spray11 Amerge (naratriptan), Axert (almotriptan), Frova (frovatriptan), Imitrex (sumatriptan), Maxalt (rizatriptan), Maxalt-MLT (rizatriptan orally disintegrating), Relpax (eletriptan), Treximet (sumatriptan/naproxen), Zomig (zolmitriptan), and Zomig-ZMT (zolmitriptan orally disintegrating) tablets, and Imitrex (sumatriptan) and Zomig (zolmitriptan) nasal spray are all indicated for the acute treatment of migraine attacks with or without aura in adults. They are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Safety and effectiveness of all of these products have not been established for cluster headache, which is present in an older, predominantly male population.
    [Show full text]
  • European Patent Office of Opposition to That Patent, in Accordance with the Implementing Regulations
    (19) TZZ _T (11) EP 2 666 772 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 409/04 (2006.01) C07D 209/16 (2006.01) 01.03.2017 Bulletin 2017/09 C07D 209/18 (2006.01) C07D 209/38 (2006.01) (21) Application number: 13173141.6 (22) Date of filing: 12.12.2003 (54) Synthesis of amines and intermediates for the synthesis thereof Synthese von Aminen und Zwischenverbindungen für die Synthese davon Synthèse d’amines et intermédiaires pour leur synthèse (84) Designated Contracting States: • DEMERSON C A ET AL: "ETODOLIC ACID AND AT BE BG CH CY CZ DE DK EE ES FI FR GB GR RELATED COMPOUNDS CHEMISTRY AND HU IE IT LI LU MC NL PT RO SE SI SK TR ANTIINFLAMMATORY ACTIONS OF SOME POTENT DI-AND TRISUBSTITUTED (30) Priority: 20.12.2002 EP 02406128 1,3,4,9-TETRAHYDROPYRANO not 3,4-B 3/4 INDOLE-I-ACETIC ACIDS", JOURNAL OF (43) Date of publication of application: MEDICINALCHEMISTRY, AMERICAN CHEMICAL 27.11.2013 Bulletin 2013/48 SOCIETY, vol. 19, no. 3, 1 March 1976 (1976-03-01), pages391-395, XP000940626, ISSN: (62) Document number(s) of the earlier application(s) in 0022-2623, DOI: 10.1021/JM00225A010 accordance with Art. 76 EPC: • HARUYASU ET ALL: "Possible metabolic 03799560.2 / 1 572 647 Intermediatesfrom IAA to beta-acid in Rice Bran", AGR. BIOL. CHEM., vol. 40, no. 12, 1976, pages (73) Proprietor: BASF SE 2465-2470, XP002714693, 67056 Ludwigshafen am Rhein (DE) • SOLL R M ET AL: "Multigram preparation of 1,8-diethyl-7-hydroxy-1,3,4,9-tetrahydropy (72) Inventors: rano[3,4-b]indole-1-acetic acid, a phenolic • Berens, Ulrich metabolite of the analgesic and antiinflammatory 79589 Binzen (DE) agent etodolac", THE JOURNAL OF ORGANIC • Dosenbach, Oliver CHEMISTRY, AMERICAN CHEMICAL SOCIETY 79415 Bad Bellingen (DE) [NOT]ETC.
    [Show full text]
  • Patient Information Leaflet
    Package Leaflet: Information for the user Sumatriptan 50 mg film-coated tablets Sumatriptan 100 mg film-coated tablets sumatriptan Read all of this leaflet carefully before you start using this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Sumatriptan tablet is and what it is used for 2. What you need to know before you use Sumatriptan tablet 3. How to use Sumatriptan tablet 4. Possible side effects 5. How to store Sumatriptan tablet 6. Contents of the pack and other information 1. What Sumatriptan tablet is and what it is used for Sumatriptan belongs to a group of medicines called serotonin receptor (5-HT1) agonists. Migraine headaches are thought to result from the dilatation of blood vessels. Sumatriptan constricts these blood vessels, thus relieving the migraine headache. Sumatriptan tablet is used to treat migraine attacks with or without aura (aura is a premonition usually connected with flashes of light, serrated images, stars or waves). 2. What you need to know before you use Sumatriptan tablet Do not use Sumatriptan tablet: - if you are allergic to sumatriptan or any of the other ingredients of this medicine (listed in section 6).
    [Show full text]
  • CT Myelogram Drugs to Avoid Hold for 48 Hours Before and 12 Hours After Your Myelogram UVA Neuroradiology
    CT Myelogram Drugs to Avoid Hold for 48 Hours Before and 12 Hours After Your Myelogram UVA Neuroradiology Generic Name (Brand Name) Cidofovir (Vistide) Acetaminophen/butalbital (Allzital; Citalopram (Celexa) Bupap) Clomipramine (Anafranil) Acetaminophen/butalbital/caffeine Clonidine (Catapres; Kapvay) (Fioricet; Butace) Clorazepate (Tranxene-T) Acetaminophen/butalbital/caffeine/ Clozapine (Clozaril; FazaClo; Versacloz) codeine (Fioricet with codeine) Cyclizine (No Brand Name) Acetaminophen/caffeine (Excedrin) Cyclobenzaprine (Flexeril) Acetaminophen/caffeine/dihydrocodeine Desipramine (Norpramine) (Panlor; Trezix) Desvenlafaxine (Pristiq; Khedezla) Acetaminophen/tramadol (Ultracet) Dexmethylphenidate (Focalin) Aliskiren (Tekturna) Dextroamphetamine (Dexedrine; Amitriptyline (Elavil) ProCentra; Zenzedi) Amitriptyline and chlordiazepoxide Dextroamphetamine and amphetamine (Limbril) (Adderall) Amoxapine (Asendin) Diazepam (Valium; Diastat) Aripiprazole (Abilify) Diethylpropion (No Brand Name) Armodafinil (Nuvigil) Dimenhydrinate (Dramamine) Asenapine (Saphris) Donepezil (Aricept) Aspirin/caffeine (BC Powder; Goody Doripenem (Doribax) Powder) Doxapram (Dopram) Atomoxetine (Strattera) Doxepin (Silenor) Baclofen (Gablofen; Lioresal) Droperidol (No Brand Name) Benzphetamine (Didrex; Regimex) Duloxetine (Cymbalta) Benztropine (Cogentin) Entacapone (Comtan) Bismuth Ergotamine and caffeine (Cafergot; subcitrate/metronidazole/tetracycline Migergot) (Pylera) Escitalopram (Lexapro) Bismuth subsalicylate (Pepto-Bismol) Fluoxetine (Prozac; Sarafem)
    [Show full text]
  • Actions of the 5-Hydroxytryptamine 1 Receptor Agonist Sumatriptan
    36 Gut 1998;42:36–41 Actions of the 5-hydroxytryptamine 1 receptor agonist sumatriptan on interdigestive Gut: first published as 10.1136/gut.42.1.36 on 1 January 1998. Downloaded from gastrointestinal motility in man J Tack, B Coulie, A Wilmer, T Peeters, J Janssens Abstract Evidence has accumulated that enteric neu- Background—Pharmacological studies of ronal 5-hydroxytryptamine (5HT) receptors the enteric nervous system have shown the are involved in regulation of the MMC in ani- presence of several subtypes of 5-hydroxy- mals and in man.3–7 In vitro studies in the tryptamine (5HT) receptor, which might guinea pig showed that 5HT4 receptors, 5HT3 be involved in control of the migrating receptors, 5HT1A receptors, and 5HT1P recep- motor complex. tors are present on myenteric neurones in the Aims—To study the eVect of sumatriptan, stomach and in the small intestine.8–11 Using an agonist of enteric neuronal 5HT1P the selective 5HT3 receptor antagonist on- receptors, on interdigestive motility in dansetron, we showed that 5HT3 receptors are man. involved in the initiation of gastric phase 3 12 Subjects and methods—In 12 healthy sub- motor activity in man. Lack of suitable jects, interdigestive motility was recorded ligands precluded a similar study for 5HT1 manometrically in the upper gastrointes- receptors and for 5HT4 receptors. Recently, tinal tract. In seven subjects blood sam- however, we showed that sumatriptan, a 5HT1 ples were drawn every 15 minutes for receptor agonist which is used in the treatment 13 radioimmunoassay of motilin and soma- of migraine in man, is an agonist of 5HT1P tostatin.
    [Show full text]